Journal
ADVANCES IN CHRONIC KIDNEY DISEASE
Volume 17, Issue 2, Pages 190-204Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2010.01.006
Keywords
Polycystic kidney disease; ADPKD; Cyclic AMP; Vasopressin V2 receptor antagonist; Mammalian target of rapamycin; Somatostatin analogs; Consortium for radiologic imaging study of PKD
Categories
Funding
- Otsuka
- Novartis
- Wyeth Pharmaceuticals
Ask authors/readers for more resources
More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available